CAMK2D(CAMK2d)
Sign in to save this workspaceUniProt Q13557 · PDB · AlphaFold · Substrate: ZIPtide + Ca-CaM* · Clone: full lengthhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 100.0% | 0.0% | 82.96 | 0.513 |
| 2 | Sunitinib | 100.0% | 0.0% | 91.73 | 0.524 |
| 3 | Alectinib | 99.5% | 0.5% | 95.49 | 0.651 |
| 4 | Midostaurin | 98.9% | 1.1% | 78.64 | 0.500 |
| 5 | Abemaciclib | 98.6% | 1.4% | 91.48 | 0.563 |
| 6 | Repotrectinib | 93.9% | 6.1% | 84.21 | 0.608 |
| 7 | Gilteritinib | 91.5% | 8.5% | 88.97 | 0.506 |
| 8 | Rabusertib | 90.9% | 9.1% | 98.74 | 0.687 |
| 9 | Ruxolitinib | 90.5% | 9.5% | 98.25 | 0.592 |
| 10 | Pacritinib | 85.7% | 14.3% | 88.64 | 0.452 |
| 11 | Bosutinib | 84.9% | 15.1% | 87.22 | 0.555 |
| 12 | Nintedanib | 83.5% | 16.5% | 90.23 | 0.608 |
| 13 | Baricitinib | 82.2% | 17.8% | 97.99 | 0.616 |
| 14 | Palbociclib | 65.0% | 35.0% | 98.75 | 0.673 |
| 15 | Ribociclib | 54.3% | 45.7% | 99.25 | 0.729 |
| 16 | Lorlatinib | 47.3% | 52.7% | 97.24 | 0.694 |
| 17 | Upadacitinib | 46.2% | 53.8% | 97.98 | 0.663 |
| 18 | Ceritinib | 45.6% | 54.4% | 95.44 | 0.618 |
| 19 | Fedratinib | 44.5% | 55.5% | 96.21 | 0.576 |
| 20 | Gefitinib | 44.3% | 55.7% | 99.25 | 0.650 |
Paralog block
CAMK2A, CAMK2B, CAMK2D, CAMK2G
EMT expression
- Mesenchymal log2(TPM+1): 4.78
- Epithelial log2(TPM+1): 3.58
- Fold change: 1.19
- Status: Upregulated
High-confidence drugs
- Rabusertib — inh 90.9% · KISS 49.45
- Ruxolitinib — inh 90.5% · KISS 43.37
- Alectinib — inh 99.5% · KISS 42.12
Selectivity landscape vs inhibition on CAMK2D
Each point is one of the 92 approved drugs; color = inhibition % on CAMK2D.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…